Combining enzalutamide with standard hormone therapy cut the risk of prostate cancer death by over 40% in a clinical trial The treatment targeted patients whose prostate cancer recurred aggressively ...
Pfizer Inc. (NYSE:PFE) on Friday released data from Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with cetuximab (marketed as ERBITUX) and mFOLFOX6 (fluorouracil, ...
A new drug combination may benefit men whose prostate cancer has returned after primary surgery or radiation therapy. Pairing enzalutamide, an androgen receptor blocker, with the hormone therapy drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results